CA2241870A1 - Macrocyclic compounds made from suboxide units - Google Patents

Macrocyclic compounds made from suboxide units Download PDF

Info

Publication number
CA2241870A1
CA2241870A1 CA002241870A CA2241870A CA2241870A1 CA 2241870 A1 CA2241870 A1 CA 2241870A1 CA 002241870 A CA002241870 A CA 002241870A CA 2241870 A CA2241870 A CA 2241870A CA 2241870 A1 CA2241870 A1 CA 2241870A1
Authority
CA
Canada
Prior art keywords
macrocyclic
com
substance according
active substance
active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002241870A
Other languages
English (en)
French (fr)
Inventor
Franz Kerek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Donatur Dr Kerek GmbH
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2241870A1 publication Critical patent/CA2241870A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/181—Heterocyclic compounds containing oxygen atoms as the only ring heteroatoms in the condensed system, e.g. Salinomycin, Septamycin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Rehabilitation Therapy (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
CA002241870A 1996-01-05 1996-12-30 Macrocyclic compounds made from suboxide units Abandoned CA2241870A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19600301A DE19600301C2 (de) 1996-01-05 1996-01-05 Durch Cyclooligomerisierung des einfachen Kohlensuboxids C¶3¶O¶2¶ aufgebaute makrocyclische Verbindungen, Verfahren zu deren Herstellung und Gewinnung sowie deren Verwendung
DE19600301.6 1996-01-05

Publications (1)

Publication Number Publication Date
CA2241870A1 true CA2241870A1 (en) 1997-07-17

Family

ID=7782233

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002241870A Abandoned CA2241870A1 (en) 1996-01-05 1996-12-30 Macrocyclic compounds made from suboxide units

Country Status (26)

Country Link
US (1) US6187810B1 (enExample)
EP (1) EP0874851B1 (enExample)
JP (1) JP4195089B2 (enExample)
KR (1) KR19990077000A (enExample)
CN (1) CN1209132A (enExample)
AR (1) AR005350A1 (enExample)
AT (1) ATE233768T1 (enExample)
AU (1) AU1307497A (enExample)
BG (1) BG102599A (enExample)
BR (1) BR9612430A (enExample)
CA (1) CA2241870A1 (enExample)
CZ (1) CZ208898A3 (enExample)
DE (2) DE19600301C2 (enExample)
EE (1) EE9800211A (enExample)
ES (1) ES2194128T3 (enExample)
HR (1) HRP970002A2 (enExample)
HU (1) HUP9904191A2 (enExample)
IL (1) IL125165A0 (enExample)
JO (1) JO1945B1 (enExample)
PL (1) PL327657A1 (enExample)
SI (1) SI0874851T1 (enExample)
SK (1) SK88598A3 (enExample)
TR (1) TR199801288T2 (enExample)
TW (1) TW376386B (enExample)
WO (1) WO1997025333A2 (enExample)
ZA (1) ZA9714B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO280796A0 (en) * 1996-10-07 1996-10-31 Austin Research Institute, The Methods of activating or enhancing FC receptors
DE10260537A1 (de) 2002-12-21 2004-07-15 Kerek, Franz, Dr. Peptide mit hohem Cysteingehalt
US20060067055A1 (en) * 2004-09-30 2006-03-30 Heffner Kenneth H Thermally conductive composite and uses for microelectronic packaging
US20080007890A1 (en) * 2004-09-30 2008-01-10 Harmon Julianne P Thermally conductive composite and uses for microelectronic packaging
CN119613750B (zh) * 2024-12-10 2025-08-12 杭州师范大学 一种机械及pH双重调控的蝶形钾离子通道分子及其制备方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2565115A (en) 1948-10-28 1951-08-21 Squibb & Sons Inc Method of obtaining a conjugated estrogen preparation
US2720483A (en) 1951-02-21 1955-10-11 Olin Mathieson Method of obtaining a conjugatedestrogen preparation

Also Published As

Publication number Publication date
DE69626548D1 (de) 2003-04-10
WO1997025333A2 (en) 1997-07-17
US6187810B1 (en) 2001-02-13
BR9612430A (pt) 1999-12-28
ES2194128T3 (es) 2003-11-16
SK88598A3 (en) 1998-12-02
AU1307497A (en) 1997-08-01
ZA9714B (en) 1997-07-23
DE69626548T2 (de) 2003-12-24
TR199801288T2 (xx) 1998-11-23
WO1997025333A3 (en) 1997-12-24
DE19600301C2 (de) 1999-12-09
PL327657A1 (en) 1998-12-21
TW376386B (en) 1999-12-11
SI0874851T1 (en) 2003-10-31
CN1209132A (zh) 1999-02-24
JO1945B1 (en) 1997-12-15
IL125165A0 (en) 1999-01-26
KR19990077000A (ko) 1999-10-25
ATE233768T1 (de) 2003-03-15
HUP9904191A2 (hu) 2000-05-28
EP0874851B1 (en) 2003-03-05
AR005350A1 (es) 1999-04-28
JP2000503015A (ja) 2000-03-14
HRP970002A2 (en) 1998-04-30
BG102599A (en) 1999-03-31
JP4195089B2 (ja) 2008-12-10
EP0874851A2 (en) 1998-11-04
EE9800211A (et) 1998-12-15
DE19600301A1 (de) 1997-07-10
CZ208898A3 (cs) 1998-10-14

Similar Documents

Publication Publication Date Title
Moore et al. Toxins from cyanophytes belonging to the Scytonemataceae
JPS6210240B2 (enExample)
US4603137A (en) Immunosuppressive chromone alkaloid
JPH01157995A (ja) 鎮痛−抗炎症活性を有するガングリオシドの内部エステル
US7199099B2 (en) Methanobactin: a copper binding compound having antibiotic and antioxidant activity isolated from methanotrophic bacteria
US5858971A (en) Cyclic peptide and method of making same by culturing a strain of actinomyces S. nobilis
EP0874851B1 (en) Macrocyclic compounds made from carbon suboxide units
EP1008345A1 (en) Antiallergic agents
US5856487A (en) Application of protoberberine alkaloid, berberine, an immunosuppressive agent
US4831053A (en) Composition for prophylaxis and therapy of hepatitis
US4233291A (en) Novel biological substance from a fungus and the process for producing the same
JP2647882B2 (ja) 鮫組織から単離した有効成分
US4895872A (en) Immunosupressive analogues and derivatives of succinylacetone
SU1056901A3 (ru) Способ получени сесквитерпеновых производных или их солей
JPH10120563A (ja) 免疫抑制剤
TWI426916B (zh) 具有護肝功效之樟芝多醣體
JPH0761993A (ja) 茶葉サポニン類の製造法及び茶葉サポニン類を含む薬剤
Tashmukhamedov et al. Arenobufagin and gamabufotalin from the venom of the Central Asian green toad Bufo viridis. Introduction, structural—functional features
JP2000103789A (ja) プロポリス由来のベンゾピラン誘導体の生理活性
JP2001515861A (ja) 抗腫瘍薬としてのジチオロピロロンおよびそれらの対応するモノオキサイドおよびジオキサイド
CN101553238A (zh) 具有保肝作用的组合物
US5656601A (en) Acylated splenopentins, methods for their synthesis and their use
JPH02184699A (ja) “８−アミノ酸”に改良のある新規シクロスポリン誘導体
JP2000510450A (ja) 群体ホヤ類のリッソクリヌム種からの環状ヘプタ―ペプチド誘導体
US5216005A (en) Immunosuppressive analogues and derivatives of succinylacetone

Legal Events

Date Code Title Description
FZDE Discontinued